Su-Jun Zheng1, Feng Qu2, Jun-Feng Li3, Jing Zhao1, Jing-Yun Zhang1, Mei Liu1, Feng Ren1, Yu Chen1, Jin-Lan Zhang4, Zhong-Ping Duan5. 1. Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University, Beijing, China. 2. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. 3. Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University, Beijing, China; Institute of Infectious Diseases, Department of Infectious Diseases, the First Hospital of Lanzhou University, Lanzhou, China. 4. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address: zhjl@imm.ac.cn. 5. Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University, Beijing, China. Electronic address: duan2517@163.com.
Abstract
OBJECTIVE: To explore the relation between serum sphingolipids and hepatic injury in chronic HBV infection. METHODS: A cohort of participants including 48 healthy persons, 103 chronic HBV-infected patients containing chronic hepatitis B (CHB) and HBV-related cirrhosis were included. High performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) was performed to detect serum sphingolipids. The serological indicators were detected and quantified. The valid liver biopsy specimens were acquired from twenty five CHB. RESULTS: Twenty four serum sphingolipids were detected. There were eighteen sphingolipids showing significant differences between the healthy control and chronic HBV infection groups. In patients with chronic HBV infection, fourteen sphingolipids differed significantly between CHB and HBV-related cirrhosis. Among sphingolipids with a significant difference in both HBV infection vs healthy control and CHB vs cirrhosis, seven sphingolipids were independently related to the presence of cirrhosis. SM(d18:1/24:0), a sphingomyelin (SM) compound, was found to have a negative correlation with model for end-stage liver disease (MELD) score. Additionally, SM(d18:1/24:0) was demonstrated to have a correlation with inflammation grades by liver biopsy in CHB patients. CONCLUSIONS: Serum sphingolipids have close relation with hepatic injury in chronic HBV infection, especially that SM(d18:1/24:0) might be a potential serum biomarker.
OBJECTIVE: To explore the relation between serum sphingolipids and hepatic injury in chronic HBV infection. METHODS: A cohort of participants including 48 healthy persons, 103 chronic HBV-infectedpatients containing chronic hepatitis B (CHB) and HBV-related cirrhosis were included. High performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) was performed to detect serum sphingolipids. The serological indicators were detected and quantified. The valid liver biopsy specimens were acquired from twenty five CHB. RESULTS: Twenty four serum sphingolipids were detected. There were eighteen sphingolipids showing significant differences between the healthy control and chronic HBV infection groups. In patients with chronic HBV infection, fourteen sphingolipids differed significantly between CHB and HBV-related cirrhosis. Among sphingolipids with a significant difference in both HBV infection vs healthy control and CHB vs cirrhosis, seven sphingolipids were independently related to the presence of cirrhosis. SM(d18:1/24:0), a sphingomyelin (SM) compound, was found to have a negative correlation with model for end-stage liver disease (MELD) score. Additionally, SM(d18:1/24:0) was demonstrated to have a correlation with inflammation grades by liver biopsy in CHB patients. CONCLUSIONS: Serum sphingolipids have close relation with hepatic injury in chronic HBV infection, especially that SM(d18:1/24:0) might be a potential serum biomarker.
Authors: Ayse L Mindikoglu; Antone R Opekun; Nagireddy Putluri; Sridevi Devaraj; David Sheikh-Hamad; John M Vierling; John A Goss; Abbas Rana; Gagan K Sood; Prasun K Jalal; Lesley A Inker; Robert P Mohney; Hocine Tighiouart; Robert H Christenson; Thomas C Dowling; Matthew R Weir; Stephen L Seliger; William R Hutson; Charles D Howell; Jean-Pierre Raufman; Laurence S Magder; Cristian Coarfa Journal: Transl Res Date: 2017-12-12 Impact factor: 7.012
Authors: Jasmine Lee-Barber; Taylor E English; Jacquelyn F Britton; Nara Sobreira; Jason Goldstein; David Valle; Hans Tomas Bjornsson Journal: JIMD Rep Date: 2018-06-20
Authors: Victoria Therese Mücke; Katja Jakobi; Viola Knop; Dominique Thomas; Marcus Maximilian Mücke; Kai-Henrik Peiffer; Stefan Zeuzem; Christoph Sarrazin; Josef Pfeilschifter; Georgios Grammatikos Journal: PLoS One Date: 2018-11-15 Impact factor: 3.240
Authors: Johannes C Schoeman; Jun Hou; Amy C Harms; Rob J Vreeken; Ruud Berger; Thomas Hankemeier; Andre Boonstra Journal: Genome Med Date: 2016-06-10 Impact factor: 11.117
Authors: Elisabeth M Haberl; Thomas S Weiss; Georg Peschel; Kilian Weigand; Nikolai Köhler; Josch K Pauling; Jürgen J Wenzel; Marcus Höring; Sabrina Krautbauer; Gerhard Liebisch; Christa Buechler Journal: Int J Mol Sci Date: 2021-05-18 Impact factor: 5.923